Make it
Laverdia®-CA1 is a novel treatment option for canine lymphoma that is affordable and convenient.
It is an oral tablet, so you can treat your dog in the comfort of your own home
LAVERDIA®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526
LAVERDIA®-CA1
The power to treat lymphoma in a pill.
When might your veterinarian prescribe Laverdia®-CA1 (verdinexor tablets)?
Just Diagnosed
Not Pursuing Conventional Chemotherapy
A convenient and affordable option when choosing to not pursue conventional chemotherapy.
Referred to Oncologist
Waiting for First Appointment
Canine lymphoma is aggressive. Laverdia®-CA1 can be used while waiting for your referral appointment in consultation with your oncologist.
Relapsed
Treatment Doesn't Have to Stop
LAVERDIA®-CA1 can be used after relapse.
If your dog has lymphoma
ask your veterinarian about
LAVERDIA®-CA1
LAVERDIA®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526.
What does conditional approval mean?
For a veterinary drug to receive conditional approval, it must be shown to be safe when used according to the label. It must also demonstrate a “reasonable expectation of effectiveness,” but has not yet proven that it meets the “substantial evidence” standard of effectiveness for full approval. While a drug is conditionally approved it is not to be used for any extra-label species or indications.
A novel treatment option
for canine lymphoma patients
Important Safety Information:
For use in dogs only. Laverdia®-CA1 (verdinexor tablets) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA®-CA1. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer Laverdia®-CA1 or come into contact with the feces, urine, saliva, or vomit of treated dogs for 3 days following treatment. LAVERDIA®-CA1 may affect female and male fertility. Wear protective disposable chemotherapy resistant gloves when handling Laverdia®-CA1 to avoid direct exposure to moistened, broken or crushed tablets or feces, urine, saliva or vomit from the treated dog. Do not use in dogs that are pregnant, nursing puppies or intended for breeding. Frequent check-ups by your veterinarian are necessary to determine whether your dog is responding to treatment, and to decide whether your dog should continue treatment with Laverdia®-CA1. The most commonly reported adverse reactions in dogs include decreased/loss of appetite, weight loss, vomiting, diarrhea, lethargy, excessive urination, excessive thirst, elevated liver enzymes, and low blood platelet count. Please see Client information Sheet and package insert for full product information.
Convenient
Twice weekly at-home oral administration
Affordable
Priced to make treatment possible for more pets
Targeted
Kills lymphoma cells while generally sparing healthy cells